| Mark Erlander |
Mark Erlander is currently the Chief Executive Officer & Director at Cardiff Oncology, Inc. He previously held positions as the Chief Scientific Officer at Biotheranostics, Inc., Assistant Professor at The Scripps Research Institute, Chief Scientific Officer at Gensignia Life Sciences, Inc., and Chief Scientific Officer at Arcturus Studios Holdings, Inc. He also worked as a Principal at Johnson & Johnson. Dr. Erlander holds a doctorate degree from the University of California, Los Angeles, a graduate degree from Iowa State University, and an undergraduate degree from the University of California, Davis. |
| Tod Smeal |
Tod Smeal is currently the Chief Scientific Officer at Cardiff Oncology, Inc. He previously held positions as the Director-Oncology Research Unit at Pfizer Inc. from 2003 to 2015, the Chief Scientific Officer at Eli Lilly & Co. from 2015 to 2020, and the Chief Scientific Officer at Hexagon Bio, Inc. from 2020 to 2021. Dr. Smeal obtained his undergraduate degree from the Massachusetts Institute of Technology and his doctorate degree from the University of California San Diego. |
| James E. Levine |
James E. Levine is currently the Chief Financial Officer at Cardiff Oncology, Inc. He previously held positions as the Chief Executive Officer & Director at Annai Systems, Inc., the President & Chief Executive Officer at Verenium Corp., and the President, Chief Executive & Financial Officer at Sapphire Energy, Inc. He also served as the Director at Biotechnology Innovation Organization and the Managing Director-Power & Utilities Group at Goldman Sachs & Co. LLC. Prior to his current role, he was the Chief Financial Officer at Cidara Therapeutics, Inc. Mr. Levine obtained his undergraduate degree from Brandeis University and an MBA from The Wharton School of the University of Pennsylvania. |
| Vicki Kelemen |
Vicki Kelemen is currently the Chief Operating Officer at Cardiff Oncology, Inc. She started this position in 2020. Prior to her current role, she attended the University of California, Davis where she obtained an undergraduate degree. |
| Fairooz Kabbinavar |
Fairooz Kabbinavar is currently the Chief Medical Officer at Cardiff Oncology, Inc. Prior to this, Dr. Kabbinavar held the position of Senior Vice President-Clinical Development at Tocagen, Inc. Dr. Kabbinavar also served as a Professor at the University of California, Los Angeles from 1991 to 2016. Additionally, Dr. Kabbinavar was the Head-Global Research & Development at HUYA Bioscience International LLC from 2021 to 2023. Dr. Kabbinavar obtained undergraduate and doctorate degrees from Nagpur University. |
| Rodney S. Markin |
Dr. Rodney S. Markin is a Chairman at Cardiff Oncology, Inc., a Chairman at InterLink AI, Inc., a Courtesy Professor-Psychiatry & Surgery at University of Nebraska and a Vice President-Network Development at Nebraska Medicine. He is on the Board of Directors at Afaxys, Inc., Childrens Hospital & Medical Center Foundation, Make-A-Wish Foundation, Inc., Mikroscan Technologies, Inc. and Keck Graduate Institute of Applied Life Sciences. Dr. Markin was previously employed as a Chairman by Transgenomic, Inc., an Associate Vice Chancellor-Business by University of Nebraska Medical Center, a Chief Executive Officer by LAB-InterLink, and a Chairman, President & Chief Executive Officer by UNMC Physicians. He also served on the board at Paradigm Diagnostics, Inc., Nebraska Surgical Solutions, Inc. and Nobl, Inc. He received his undergraduate degree from Nebraska Wesleyan University, a doctorate degree from the University of Nebraska Medical Center and a doctorate degree from The University of Nebraska-Lincoln. |
| Lâle White |
Ms. Lâle White is an Independent Director at Cardiff Oncology, Inc., a Member at The California Clinical Laboratory Association and an Executive Chairman & Chief Executive Officer at XIFIN, Inc. She is on the Board of Directors at Cardiff Oncology, Inc. Ms. White was previously employed as an Independent Director by CombiMatrix Corp., a Vice President-Finance by Laboratory Corporation of America, Inc., an Executive Chairman by Biotheranostics, Inc., and a Vice President-Finance by Laboratory Corp. of America Holdings. She also served on the board at Avista Public Acquisition Corp. II. She received her undergraduate degree from Florida International University and an MBA from Florida International University. |
| Renee P. Tannenbaum |
Dr. Renee P. Tannenbaum is an Independent Director at ANI Pharmaceuticals, Inc. and an Independent Director at Cardiff Oncology, Inc. She is on the Board of Directors at ANI Pharmaceuticals, Inc. and Cardiff Oncology, Inc. Dr. Tannenbaum was previously employed as a Vice President-Global Partnering by Halozyme, Inc., an Independent Director by Zogenix, Inc., a Head-Global Customer Excellence by AbbVie, Inc., an Independent Director by Sharps Compliance Corp., a President by Myrtle Potter & Co. LLC, a Chief Commercial Officer & Executive VP by Elan Pharmaceuticals, Inc., and a Professor by University of the Sciences in Philadelphia. She also served on the board at Nordic Nanovector ASA, Cipher Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. and The Bay Area Bioscience Association. She received her undergraduate degree from the University of Connecticut, an MBA from Temple University (Pennsylvania), a doctorate degree from the University of Connecticut and a doctorate degree from Philadelphia College of Pharmacy. |
| Gary W. Pace |
Dr. Gary W. Pace is an Independent Director at Cardiff Oncology, Inc., a Chairman at Sova Pharmaceuticals, Inc., a Partner & Investment Committee Chair at Pacific Channel Ltd., an Independent Director at Pacira Biosciences, Inc., an Executive Chairman at View Point Medical, Inc. and a Professor at The University of Queensland. He is on the Board of Directors at Cardiff Oncology, Inc., Pacira Biosciences, Inc., Curtana Pharmaceuticals, Inc., Immunicom, Inc., NeuroMedix, Inc., Protiveris, Inc., Sacron Innovations Pty Ltd. and Upstream Medical Technologies Ltd. Dr. Pace was previously employed as an Independent Non-Executive Director by Invitrocue Ltd., an Independent Non-Executive Director by Simavita Ltd., an Independent Non-Executive Director by Antisense Therapeutics Ltd., an Independent Director by Transition Therapeutics, Inc., an Independent Non-Executive Director by QRxPharma Ltd., a Chairman & Chief Executive Officer by Waratah Pharmaceuticals, Inc., a President & Chief Executive Officer by RTP Pharma, Inc, an Independent Director by ResMed, Inc., a Founder by Transcend Therapeutics, Inc., a Senior Vice President-Research & Development by Clintec, and a Vice Chairman by Hunter Immunology Pty Ltd. He also served on the board at Engender Technologies Ltd., Footfalls & Heartbeats (UK) Ltd., Peplin, Inc., Peplin Ltd., Celsion Corp., AVACEN, Inc. and Breathe Easy Ltd. He received his undergraduate degree from The University of New South Wales and a doctorate degree from Massachusetts Institute of Technology. |
| James O. Armitage |
Dr. James O. Armitage, MD, is an Independent Director at Cardiff Oncology, Inc. and a Professor-Internal Medicine at University of Nebraska Medical Center. He is on the Board of Directors at Cardiff Oncology, Inc. and Tesaro, Inc. Dr. Armitage was previously employed as a President by American Society for Blood & Marrow Transplantation and a President & Director by American Society of Clinical Oncology, Inc. He also served on the board at MGI PHARMA, Inc. He received his undergraduate degree from the University of Nebraska and a doctorate degree from the University of Nebraska Medical Center. |
| Mani Mohindru |
Mani Mohindru founded Immtox LLC in 2012. Dr. Mohindru also currently works at Cardiff Oncology, Inc., as Independent Director from 2021 and CytomX Therapeutics, Inc., as Independent Director from 2020. Dr. Mohindru also formerly worked at CereXis, Inc., as Chief Executive Officer from 2019 to 2020, Novasenta, Inc., as Chief Executive Officer & Director from 2021 to 2024, Capstone Investments, as Managing Director, SAB Sciences, Inc., as Director from 2020 to 2021, Credit Suisse Securities (USA) LLC (Broker), as Research Analyst, Curis, Inc., as Chief Strategy Officer from 2016 to 2017, UBS Securities LLC, as Research Analyst, CARA Therapeutics, Inc., as Chief Financial & Strategy Officer from 2017 to 2019, ThinkEquity LLC, as Analyst, and Axon Healthcare Ltd., as Partner from 2009 to 2011. Dr. Mohindru received her doctorate degree in 2003 from Northwestern University and undergraduate degree and graduate degree from All India Institute of Medical Sciences. |
